High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: The experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party

Creative Commons License

De Giorgi U., Blaise D., Lange A., Viens P., Marangolo M., Madroszyk A., ...Daha Fazla

BONE MARROW TRANSPLANTATION, cilt.40, sa.11, ss.1045-1048, 2007 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 11
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1038/sj.bmt.1705880
  • Dergi Adı: BONE MARROW TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1045-1048
  • Anahtar Kelimeler: non-small cell lung cancer, high-dose chemotherapy, peripheral blood progenitor cells, carboplatin, COLONY-STIMULATING FACTOR, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, SURVIVAL, STANDARD
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

We report the experience of the EBMT Solid Tumours Working Party (STWP) using high-dose chemotherapy (HDCT) with PBPC support in patients with non-small cell lung cancer (NSCLC). Between 1989 and 2004, 36 NSCLC patients (27 men and 9 women), median age 53.5 years (range: 24-62) were treated with 63 HDCT courses. A high-dose carboplatin-based regimen was used in 53% of the cases. Thirty-two patients had relapsed/metastatic disease, while four classified as stage IIIB received HDCT followed by radiotherapy. No treatment- related death occurred. Of 25 patients who were planned to receive multi-cycle HDCT, 4 cases (16%) interrupted the treatment early due to prolonged severe toxicities and 4 (16%) due to progressive disease. Of 36 evaluable patients, 3 (8%) achieved a complete remission and 13 (36%) had a partial remission at an overall response rate of 44%. Of these, one patient with stage IIIB and one with stage IV are alive disease free at 71+ and 149+ months, respectively. After a median follow-up of 48 months (range: 6-149), median survival was 7 months (range: 1-149). Despite one anecdotal case, HDCT did not show significant activity, but induced relevant morbidity in NSCLC patients.